Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
SNDXSyndax(SNDX) Prnewswire·2024-11-12 20:00

–      Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients (p-value = 0.0014) ––      47% (30/64) ORR in a heavily pre-treated population, including 75% with prior venetoclax exposure in the efficacy population ––      Favorable safety and tolerability profile; only 5% of patients discontinued due to treatment-related adverse events ––      Results highlight consistency of revumenib's compelling clinical profile ––      sNDA filing in R/R mNPM1 AML expected in 1H25, ...